Transdermal administration of estradiol eliminates first-pass hepatic metabolism and may theoretically reduce the risk of venous thromboembolism (VTE) associated with oral estrogen.
A small, open-label randomized trial was conducted to compare the pharmacokinetics of ethinyl estradiol (EE) when administered in one of three ways: (1) the vaginal ring (Nuvaring, 15 mcg EE), (2) the transdermal patch (OrthoEvra, 20 mcg EE), or (3) a combination oral contraceptives (OCs) (Levlen, 30 mcg EE). The participants were 24 healthy, nonobese women (mean age 23, 25, or 26, depending on group assignment). They received one of the three preparations for 21 days.
The total exposure to EE (defined as the area under the curve) in the patch group was 3.4 times higher than the ring group and 1.6 times higher than the OC group (P<.05 for both comparisons). The peak EE exposure in the OC group was 4.5 times higher than the ring group and 1.6 times higher than the OC group (P<.05 for both comparisons). Individual variations in serum EE levels were greatest in the patch group while dayto-day variations were greatest in the OC group.
The study was limited by its small size and was not powered for major or minor adverse events. Several authors were employed by the ring manufacturer. Obese women were not included because it is known that the patch is less effective in obese patients.
In response to these findings, the FDA updated the OrthoEvra contraceptive patch labeling to warn that the patch exposes women to 60% more total estrogen than typical OCs. 1 It is unknown if higher estrogen exposure translates into greater clinical risks and whether total exposure is a better marker for risk than peak exposure. A recent study 2 did suggest a slight, but not statistically significant, increased nonfatal VTE risk for the patch compared to a 35-mcg EE/ norgestimate OC (5.3 vs 4.2 events per 10,000 womenyears, P>.05); note that the risk is about 1 per 10,000 in nonusers). The potential risks of hormonal contraception must be balanced with the potential risks of pregnancy. Compliance with the weekly patch may be better than with a daily OC; alternatives include injectables, ring, IUD, and sterilization. Patients with VTE or cardiovascular risk factors should be counseled about alternatives to patch contraception.
FDA Advisory: Paroxetine Increases Risk of Fetal Heart Defects U.S. Food and Drug Administration. Public health advisory: Paroxetine. Available at: http://www.fda.gov/cder/drug/ advisory/paroxetine200512.htm.
Depression is a common problem, particularly in reproductive-age women where the estimated prevalence is 10-20%. Frequently, serotonin reuptake inhibitors (SRIs) are used to treat depression, although their safety in pregnancy is uncertain. The FDA, because of safety concerns with first-trimester use of one SRI, Paxil (paroxetine), asked the manufacturer to investigate paroxetine's association with fetal anomalies.
The manufacturer submitted two studies: one using a Swedish national registry (including more than 6,800 women) and one using a U.S. insurance claims database (including more than 5,900 women). 3 In the Swedish study, women who received paroxetine in early pregnancy had increased risk of having an infant with a cardiac defect compared to the entire registry population (2% of paroxetineexposed infants had defects vs 1% of all infants, odds ratio [OR] 1.8, 95% confidence interval [CI] 1.1-2.8). In the U.S. study, women who received paroxetine in the first trimester had a nonsignificant increased risk of having an infant with cardiac malformations (OR 1.5, 95% CI 0.8-2.9) and an increased risk of having an infant with any congenital malformation (OR 1.8, 95% CI 1.2-2.8) compared to women who received other antidepressants in the first trimester. Most of the cardiac defects were atrial or ventricular septal defects.
As manufacturer reports, these data are not published in a peer-reviewed journal. Studies conducted by the manufacturer may be theoretically biased by a manufacturer's motivation to present its product in a positive light. However, in this case, these reports were requested by the FDA and the main finding was significant harm with the product.
The FDA has changed the pregnancy category of paroxetine from C (safety uncertain) to D (evidence of harm). Thus, any woman at risk for pregnancy should not be given paroxetine. Other antidepressants may be prescribed after a discussion of risks and benefits; competing SRIs and bupropion generally are pregnancy category C. Mild depression may be treated with cognitive or behavioral therapy. Women on an SRI who are pregnant or planning pregnancy should be evaluated for SRI discontinuation and counseled about depression relapse. Depression relapse is more frequent in women discontinuing antidepressants early in pregnancy than in women continuing them (68% vs 26%) 4 (see article summary in the Appendix). In some patients, especially women with highly recurrent depression or depression of long duration, the benefits of continuing an antidepressant may be greater than the risk to the fetus (untreated depression can also lead to poor pregnancy and infant outcomes).
Women on an SRI during their third trimester should be also counseled about effects of late SRI use, including a low risk of neonatal pulmonary hypertension and infant behavioral problems 5, 6 (see article summaries in the Appendix). These risks must be balanced with benefits: third-trimester antidepressants may prevent postpartum depression and neonatal well-being depends on a mother free of depression. Both flexible sigmoidoscopy and colonoscopy are supported as colorectal cancer (CRC) screening options, but the availability of colonoscopy is limited. Some have suggested, because women have lower age-adjusted CRC rates, that flexible sigmoidoscopy is a reasonable alternative for CRC screening in women.
Women were recruited from military centers for two groups: average risk and higher risk. More than 1,400 women were enrolled; about 1,200 were on average risk, asymptomatic women, aged 50-79, who were referred for CRC screening; and 200 were asymptomatic women, aged 40-79, with a firstdegree relative with colon cancer ("family history group"). Men from a VA cooperative study were age-and risk factor-matched to enrolled women. All underwent colonoscopy only, and lesions in the rectum and sigmoid were defined as "within reach of flexible sigmoidoscopy".
About 5% of average-risk women and 7% of family history women had advanced neoplasia, defined as adenomas ≥1 cm, villous adenomas, high-grade dysplasia, or invasive cancer. Among average-risk women, flexible sigmoidoscopy alone would have found advanced neoplasia in 1.7% but missed it in 3.2%. If colonoscopy were the gold standard, flexible sigmoidoscopy would have a similar sensitivity in detecting advanced neoplasia in both risk groups (30-35%) .
In the 50-to 69-year-old age group, men were more likely to have advanced neoplasia than women, 8.6% versus 4.5% (P= .002). If the clinical strategy was to perform a colonoscopy if any size adenoma was found on flexible sigmoidoscopy, then 35% of advanced neoplasia would be found among women, compared to 66% among men.
Flexible sigmoidoscopies were not actually performed on the study participants (the colonoscopic findings were used as a surrogate), but a gender-based bias is unlikely. In addition, military populations lessen generalizability.
In conclusion, compared to men, women have a lower percentage of distal neoplasia. Thus, despite the lower prevalence of advanced neoplasia in women compared to men, flexible sigmoidoscopy would miss substantial absolute numbers of neoplastic lesions in both genders. Thus, if both are available, it appears difficult to recommend flexible sigmoidoscopy over colonoscopy for women. It is hypothesized that low intake of dietary fat leads to low estrogen levels, which decrease breast cancer risk. Indeed, diets high in fat are linked to increased breast cancer incidence in some ecologic studies, but other studies are conflicting. Observational studies examining effects of diet are often limited by measurement and recall biases. The Women's Health Initiative (WHI) directly assessed the benefits and risks of a low-fat diet in a randomized controlled trial (RCT). Its primary outcomes were breast and CRC 7 (see article summary in the Appendix). A secondary cancer outcome was coronary heart disease (CHD) 8 (see article summary in Appendix).
Eligible participants were healthy postmenopausal women, aged 50-79, without breast or CRC, who were consuming at least 32% of energy from fat at baseline. More than 48,000 were randomized asymmetrically because of cost: 40% to an intensive low-fat diet intervention and 60% to usual diet. Intervention diet goals were <20% energy from fat, 5 servings daily of fruits or vegetables, 6 servings daily of grains, and weight maintenance. Intervention participants received customized fat goals, 18 group sessions in the first year, and quarterly sessions thereafter. Self-reports of breast cancer were confirmed by chart review. At baseline, mean age was 62 and mean BMI was 29. Compared to the control group, the intervention group consumed 11% less calories from fat at year 1, and 8% less at year 6. At 1 year, the intervention women weighed 2.2 kg less; at 7.5 years, they weighed 0.4 kg less. Among a sample of 300 women, estradiol levels fell slightly more among intervention patients; estrone levels did not differ.
After a mean follow-up of 8.1 years, 655 (3.4%) of the women in the intervention group had developed breast cancer, compared to 1,072 (3.7%) women in the control group (P=.07; hazard ratio [HR] 0.91, 95% CI 0.83-1.01). Women with a higher fat consumption at baseline had a slightly greater reduction in breast cancer risk.
Women enrolled in the low-fat diet trial could participate in the other WHI trials (17% were in a hormone therapy trial and 50% were in the calcium + vitamin D trial); hormones are known to affect breast cancer risk, but did not appear to be a significant interaction in this analysis. Whereas the intervention group had lower fat intake than the control group, the trial is limited by the fact that relatively few women (31% at year 1, 14% at year 6) achieved the goal for dietary fat intake.
An intervention targeting fat stores instead of dietary fat intake may have been more effective. Among postmenopausal women, the main source of circulating estrogen is conversion of androgens to estrogens by aromatase in the adipose tissue. Thus, body stores of adipose tissue may be more important than fat intake. Based on this study and other literature relating postmenopausal obesity to breast cancer, it is reasonable to advise women concerned about their breast cancer risk to maintain a normal weight, rather than follow a low-fat diet. Calcium supplementation is recommended to prevent osteoporosis and fractures, but previous trials have been small and conflicting. This study aimed to determine the efficacy of vitamin D and calcium in preventing hip and, secondarily, other fractures. It is a major constituent of the WHI series of trials.
Calcium Supplementation Above 1,100 mg Not Helpful in Preventing Osteoporotic Fractures
More than 35,000 healthy postmenopausal women ages 50-79 were randomized to calcium carbonate 1,000 mg plus vitamin D 400 IU or placebo and were followed 7 years. About 50% were on hormone therapy. Self-reported fractures were confirmed by review of radiographs.
Baseline intake was about 1,100 mg/day of calcium and 360 IU/day of vitamin D in both groups. There was no difference between groups in the risk of hip, vertebral, wrist, or total fractures (hip HR 0.88, 95% CI 0.72-1.08; vertebral HR 0.90, 95% CI 0.74-1.10). An increased risk in kidney stones was seen in the intervention group (HR 1.17; 95% CI 1.02-1.34). In a subgroup with dual x-ray absorptiometry measurements at 3, 6, and 9 years, there was a statistically significant reduction in bone loss at the hip (P<.01), but not at other sites.
The study was limited by a low rate of adherence to study medications: at the end of the trial, only 59% of the study participants were taking at least 80% of their assigned medication. Women in both groups were allowed to take personal calcium supplements. Because the baseline calcium and vitamin D intake was high, this study did not test supplementation among those with low baseline intakes. Finally, this study was underpowered for hip and vertebral fracture reduction (the fracture rate among control subjects was about half the expected rate).
This study does not offer a compelling reason to abandon the conventional strategy to supplement women to a daily calcium intake (dietary plus supplements) of 1,200 mg/day. There is insufficient evidence to supplement above 1,100 mg/day. Women should be counseled about a possible increased risk of kidney stones with calcium and vitamin D supplements at high levels. Other nonpharmacologic therapies (e.g., weight-bearing exercise and smoking cessation) should be discussed along with calcium supplementation. Other recent studies of calcium and vitamin D supplemen- Higher dose vitamin D supplementation (700-800 IU/day) reduced hip fracture risk (relative risk [RR] 0.74, 95% CI 0.61-0.88), whereas 400 IU/day did not (RR 1.15, 95% CI 0.88-1.50). Results were consistent in the ambulatory and institutionalized settings and between hip and nonvertebral fracture outcomes. The number needed to be treated with high-dose vitamin D supplementation was 45 persons to prevent 1 hip fracture and 27 to prevent 1 nonvertebral fracture.
Calcium supplementation was variable across trials: from no recommendation to dietary recommendation to supplements from 500 to 1,200 mg. Follow-up also varied, from 1 to 5 years. The majority of participants were white, which limits generalizability.
Vitamin D is inexpensive, easily available, and prevents nonvertebral fractures. All trials in this meta-analysis studied cholecalciferol (D3), rather than ergocalciferol (D2). To determine which form of vitamin D is in an over-the-counter supplement, read the ingredient list (not the supplement facts) on the bottle. Calcium supplementation is likely needed to prevent vertebral fractures 11 (see article summary in the Appendix). Postmenopausal estrogen with progestin (E + P) increases CHD risk. The principal results of the WHI trial did not find a similar harm with estrogen alone. Hsia et al. presented a detailed analysis of CHD risk with estrogen alone.
Nearly 11,000 women aged 50-79 years with a history of a hysterectomy were randomized to 0.625 mg conjugated equine estrogens (CEE) or placebo for an average of 7 years (the trial was stopped early over concerns of stroke risk). Self-report of CHD outcomes were adjudicated. Very few participants had CHD at entry, but many had CHD risk factors (primarily hypertension).
Conjugated equine estrogen did not affect risk of CHD: about 0.5% of women per year had either coronary death or MI in both groups (HR 0.95, 95% CI 0.79-1.16). Whereas CHD history or risk factors did not affect the primary outcome, younger age (50-59 vs 60-79 years, P=.07) and lower Creactive protein (<1.3 vs >1.3 mg/L, P=.04) trended toward lower CHD risk. There was no statistically significant time trend, but risk decreased after 1-2 years. This analysis is limited by the fact that it was underpowered to detect differences among age groups, but an adequately powered study would have required more than 17,000 women. In addition, fewer than half of all participants continued to take study medication at trial end.
Unlike E + P, estrogen alone appears not to confer CHD risk. The indications for estrogen use remain focused on menopausal symptoms. The decision to use estrogen in a symptomatic woman with a history of hysterectomy remains individualized and involves weighing risks (stroke, venous thromboembolic disease, cognitive impairment, and cholecystectomy) and benefits (menopausal symptom relief and osteoporotic fractures). C-reactive protein levels, duration of estrogen use, and a woman's age may alter risk-benefit profile. Estrogen with progestin confers more CHD risk than CEE alone (P<.03) and the risk-benefit profile differs (E + P increases the risk of breast cancer and decreases the risk of colon cancer). Female sexual dysfunction is common: the communitydwelling prevalence is estimated at 25-63%. This study aimed to test the efficacy and safety of a testosterone patch for female hypoactive sexual desire disorder.
Transdermal Testosterone Modestly Effective for Low Libido in Surgically Menopausal Women
The multicenter RCT included surgically menopausal women with distressful low sexual desire on estrogen therapy. Eligible women were in a stable monogamous relationship with a sexually functioning partner. About 450 women (age 24-70 years, average age 50) were randomized to testosterone patches at the doses of 150, 300, or 450 mcg/day, or placebo for 24 weeks. Primary outcomes were changes in the sexual desire domain score (from a 7-domain questionnaire) and frequency of satisfying sexual activity (from weekly diaries of sexual activity).
There was no dose-response effect, but the 300-mcg/day dose resulted in small, statistically significant improvements in sexual desire scores. Compared to placebo, the absolute effect was about 7 points on a 100-point scale. The 300-mcg/ day dose also increased the weekly number of satisfying episodes from 0.7 to 1.3, whereas placebo increased the weekly number of episodes from 0.7 to 1.0 (P<.05), yielding an absolute effect of about 1 more episode per month compared to placebo. Adverse effects were not significant. Total (but not free) testosterone levels were above the normal reference range for all testosterone doses by week 12. Primary outcomes had a significant but small (κ=0.2) correlation with free and total testosterone levels.
The trial was industry-sponsored and too short to assess long-term safety. Generalizability is limited in many ways. Results apply to a population taking considerable doses of estrogen (half were taking high-dose estrogen, i.e., >0.625 mg CEE), a population with self-described distressful low desire and yet 3 satisfying sexual episodes per month at baseline, and healthy surgically menopausal women. Also, conclusions about adverse lipid effects are limited to women with normal lipids.
This study targeted women with "female hypoactive sexual desire disorder." It is unclear how testosterone affects other sexual dysfunction disorders. The strong placebo effect highlights how simply discussing sexuality and diarying sexual episodes improves sexual well-being. Behavioral therapy should be tried first. Then consider lowering the estrogen dose (as vasomotor symptoms allow) because estrogen increases sex hormone binding globulin and thus decreases free testosterone. It is unclear whether testosterone is helpful in women with ovaries intact (who circulate ovarian testosterone) or in surgically menopausal women not taking estrogen.
The patch product is not available, so prescription of testosterone in women is limited to either oral combination of estrogen-testosterone (which may have more lipid effects than transdermal preparations that avoid the first-pass metabolism) or a modified dose of testosterone gel (FDAapproved only for men), such as a pea-sized portion of 1% gel. Any woman prescribed with testosterone should be monitored for adverse effects. Another transdermal testosterone trial reported a 10% increase in androgenic side effects such as acne, hirsutism, voice coarsening, and alopecia 12 (see article summary in the Appendix Participants could also enroll in other WHI trials. 8 y may not be long enough to detect colon cancer differences in a screened population. Diet changes were modest. A low-fat diet had no effect on colon cancer incidence over 8 y.
APPENDIX
[11] Does a low-fat diet decrease risk of CHD?
WHI low-fat diet RCT (see text). Major CHD defined as acute MI, silent MI or CHD death.
Intervention subjects had a 3.6-point greater decline in LDL values, a 0.4-point decline in HDL levels, and a 2.2 kg decline in weight. After 8 y, 2.9% of the intervention subjects had developed major CHD, compared to 2.9% of the control group, HR 0.98 (0.88-1.09).
Secondary outcome. Saturated fats were not targeted. The small change in cholesterol levels would predict a decrease in CHD risk by only 2-4%, less than what the study was powered to detect. A general low-fat diet intervention had no effect on CHD in an underpowered trial.
[12] Do diets that promote lower fat and higher carbohydrate intake promote weight gain? WHI low-fat diet RCT (see text).
Included postmenopausal women aged 50-79 y. Excluded those consuming less than 32% of energy from fat at baseline, based on self-report.
Compared to the control group, the intervention group consumed 11%
less fat calories at year 1, and 8% less at year 6. (1-84) is followed by a bisphosphonate? RCT of more than 200 osteoporotic women in 4 groups: (1) PTH for 1 y then alendronate 10 mg for 1 y, (2) PTH for 1 y then placebo for 1 y, (3) PTH and alendronate (combination group) for 1 y then alendronate for 1 y, and (4) alendronate for 2 y (control group). All 4 groups had increased spine BMD; the greatest increase was with PTH then alendronate (12%) and the smallest with PTH then placebo (4%).
The combination group was similar to the PTH then alendronate group. All 4 groups had increased hip BMD, excepting PTH then placebo.
Not designed to test differences in fracture rates. Study conducted in bisphosphonate-naive women (never taken or none for >1 y). PTH (1-84) is not available in the United States. The increase in BMD seen after 1 y of PTH (1-84) is lost after discontinuation of therapy if not followed by alendronate.
[19] Does PTH improve BMD and/ or biochemical markers of bone turnover in women who had used or were currently taking alendronate?
RCT of 126 women with osteoporosis or osteopenia and high risk of fracture, mean age 68. Randomized to 1 of 3 groups for 15 mo: (1) alendronate 70 mg weekly, (2) daily PTH 25 mcg SQ plus alendronate, and (3) cyclic PTH (3 mo on, 3 mo off) plus alendronate.
Spine BMD increased more in the PTH groups than the alendronate-alone group (6% vs no change, P<.001).
Hip
BMD increases did not differ between the groups. Bone formation indexes rose in both PTH groups, and most consistently in the daily PTH group.
Small study. Not designed to assess fracture rate. In contrast to previous studies, PTH increases BMD in women who are persistently osteoporotic after taking bisphosphonates.
Osteopenia treatment Subgroup secondary analysis of published RCT. Industrysponsored.
Osteopenic women without history of fracture may modestly benefit from prophylactic alendronate. 
Results

Limitations
Conclusions and comments
Is it cost-effective to treat osteopenic women with bisphosphonates? Cost-effectiveness model of health effects due to fractures in osteopenic women aged 55-75. The lifetime incremental cost ratios (cost of gaining 1 QALY) ranged from $70,000 to $332,000, depending on age and t-scores.
Model based on best estimates of fracture rate reduction and current cost of alendronate (many assumptions). Applicable only to white women in the United States.
Assuming that the societal willingness to pay is $50,000 per QALY, it is not cost-effective to treat osteopenic women without previous fractures.
Subclinical hypo-and hyperthyroidism: risk of heart disease
Subclinical hypothyroidism is common in women older than age 70 (about 10%). Is subclinical hypothyroidism associated with CVD in older adults?
Longitudinal cohort of more than 2,700 participants (51% women) aged 70-79 followed for 4 y. CVD diagnoses (CHF, CHD, stroke, and PAD) were adjudicated after selfreport or death. 12% had subclinical hypothyroidism (TSH> 4.5 mIU/L and normal T4). Variety of aspirin doses. Only 3 t r i a l s i n cl u d i n g wo m e n ( 5 including men). Aspirin prevents ischemic strokes in women and MIs in men, while increasing bleeding events in both. Benefits over risks are modest for primary prevention in a low-risk population: 6 y of aspirin therapy prevents 3 CVD events per 1,000 women and 4 CVD events per 1,000 men, but causes about 2.5 major bleeding events in women and 3 in men.
Sexual function [34] Does testosterone increase libido in oophorectomized women on estrogen? RCT of 300 mcg/d testosterone patch versus placebo for 6 mo in more than 550 women without ovaries and on estrogen. (Methods parallel trial in text). With testosterone, women had about 0.2 more satisfying sexual encounters weekly and about a 10-point (out of 100) increase in sexual desire score compared to placebo. Androgenic adverse events (acne, facial hair, alopecia, and voice deepening) were higher in the testosterone group, 20% versus 11% (P value not given).
Industry sponsored. Testosterone patch product not commercially available.
Testosterone patch appears to m o d e s t l y i n c r e a s e l i b i d o i n surgically menopausal women. Androgen adverse events were common.
[35] Do low levels of circulating androgens predict sexual dysfunction? Healthy, nonpregnant Australian women were recruited from a defined population to maintain an equal distribution of ages between 18 and 75. Low sexual functioning was defined as 0 on a 100-point sexual functioning scale in any of 7 domains (arousal, pleasure, orgasm, desire, responsiveness, self-image, and sexual concerns). About 5% of women in the younger age group (18-44 y) had low sexual functioning compared to 4-18% of women in the older age group (45-75 y). The domains of arousal, pleasure, and orgasm were more likely to have low scores. Total and free testosterone levels did not predict low sexual functioning. DHEAS levels correlated in some domains, but the majority of women with low DHEAS did not report sexual dysfunction.
This study did not address how hormone levels could be used to guide therapy in women with low sexual function.
Measurement of testosterone or DHEAS levels is not clinically informative in predicting low sexual function.
BMD=bone mineral density, CEE=conjugated equine estrogens, CHD=coronary heart disease, CHD=coronary heart disease, CHF=congestive heart failure, CI=confidence interval, CIN=cervical intraepithelial neoplasia, CRC=colorectal cancer, CVD=cardiovascular disease, DHEAS=dehydroepiandrosterone sulfate, E + P=estrogen + progestin, HR=hazard ratio, HT= hormone therapy, INR=International Normalized Ratio, OC=oral contraceptives, OR=odds ratio, PAD=peripheral artery disease, PTH=parathyroid hormone, QALY=quality-adjusted life year, RCT=randomized controlled trial, RR=relative risk, SRI=serotonin-reuptake inhibitor, SSRI=selective serotonin-reuptake inhibitors, WHI=Women's Health Initiative Ultra low-dose approved only for osteoporosis prevention; it does not treat menopausal symptoms.
DMPA=depomedroxyprogesterone acetate
